1. Engineer the line
- Stable BaF3 line expressing the driver kinase
- Grown in multi-well plates without IL-3
- Survival depends on the transforming kinase
BaF3 Cell Proliferation Assays
Functional confirmation of kinase inhibition in engineered, kinase-dependent BaF3 cells.
IC50 by proliferation readout across oncogenic drivers and resistance mutants, including activation-dependent cytokine-receptor models, with custom lines built to order.
From Target Binding to Cell Survival
BaF3 is a murine pro-B cell line that depends on interleukin-3 for survival. Stable expression of a transforming kinase switches the cells from IL-3 dependence to kinase dependence: proliferation is now driven by the oncogenic kinase. Inhibiting that kinase removes the survival signal and the cells undergo apoptosis. The readout is functional, confirming that target inhibition translates into loss of cell survival rather than binding alone. A separate parallel IL-3 rescue separates true on-target inhibition from non-specific cytotoxicity, which makes the BaF3 cell proliferation assay a rigorous functional endpoint in kinase drug discovery.
How the BaF3 Cell Proliferation Assay Works
2. Seed and dose
- Seed cells, add inhibitor the next day
- Activation-dependent lines receive concurrent ligand
- Run as a dose-response for IC50
3. Incubate
- Typically 72 hours (48 to 72 depending on line)
- Kinase blockade removes the survival signal, driving apoptosis
4. Read viability
- CellTiter-Glo luminescent ATP readout, antibody-free
- Signal is proportional to viable cell number
- Alamar Blue, MTT, CyQuant, or IncuCyte optional
5. Interpret with controls
- DMSO high control, staurosporine low control
- IL-3 rescue as off-target control, by request
Model Classes
Standard transforming receptors
Receptors whose overexpression confers constitutive kinase activity drive IL-3-independent growth on their own. Example: EGFR variants. These lines report inhibitor potency directly through loss of proliferation.
Activation-dependent cytokine-receptor models
Some receptors do not transform by overexpression alone and require concurrent ligand co-stimulation. EpoR (erythropoietin receptor) and MPL (thrombopoietin receptor) fall in this class, with KIT wild type available on request. These models are harder to build and extend BaF3 functional readouts to cytokine-receptor biology.
Platform Advantages
Functional endpoint on matched constructs
BaF3 confirms that target inhibition produces loss of cell survival. Run on the same targets as our binding and activity assays, it completes a binding to activity to function chain: NanoBRET, cellular phosphorylation, then BaF3 proliferation.
IL-3 rescue off-target control
Because BaF3 proliferation reverts to IL-3 dependence when IL-3 is restored, a parallel IL-3-supplemented arm distinguishes genuine on-target kinase inhibition from general compound cytotoxicity. Provided upon request.
Activation-dependent cytokine-receptor models
Ligand-co-stimulated lines go beyond simple receptor overexpression and cover cytokine-receptor and MPL (Thrombopoetin) biology that catalog proliferation panels rarely address. Ready lines include EpoR and MPL; KIT wild type is available in this class on request.
Resistance and transforming-capacity assessment
Determines whether a new mutation or fusion can transform BaF3 cells to stimulus independence, and ranks resistance across a mutant series such as the KIT compound mutants and the EGFR triple mutant. Cells expressing MPL with CALR (L367fs*46) show a transformed phenotype and proliferate without any stimulus, controlled against the MPL/CALR wild type line.
Custom, project-built lines
New oncogenic driver lines are generated on request. This is a bespoke, project-driven service rather than a fixed catalog, which suits novel drivers, fusions, and specific resistance mutations not available elsewhere.
Simple, robust luminescent readout
CellTiter-Glo provides an antibody-free ATP readout with alternative readouts available, keeping the assay reproducible and scalable for IC50 determination.
Applications
Resistance profiling
Compare inhibitor potency across a mutant series to predict and rank resistance. The KIT compound-mutant set (d557-558 combined with V654A and gatekeeper or activation-loop substitutions) and the EGFR triple mutant support next-generation inhibitor selection against known escape routes.
Transforming-capacity assessment
Determine whether a newly identified mutation or fusion can transform BaF3 cells to IL-3 independence, a direct functional test of oncogenic driver potential that informs target validation.
Off-target discrimination
Run a parallel IL-3-supplemented arm. If growth inhibition persists when kinase signaling is bypassed by IL-3, the effect is non-specific cytotoxicity rather than on-target inhibition.
Cytokine-receptor and MPL models
Activation-dependent EpoR and MPL lines extend functional testing to ligand-driven receptor systems. For myeloproliferative neoplasm biology, BaF3 cells expressing MPL with mutant calreticulin (L367fs*46) are transformed and proliferate without stimulus, run against the MPL/CALR wild type control line.
Custom line generation
New driver lines are built to order as a project deliverable. This is the primary route for programs targeting novel kinases, fusions, or specific resistance mutations, and it can feed directly into downstream in vivo oncology work.
Available Lines
| Cell Line | Driver Target | Model Class | Activation |
| EGFR | EGFR, wild type | Standard transforming receptor | Constitutive on overexpression |
| EGFR (d746-750/T790M/C797S) | EGFR, triple mutant | Resistance model | Constitutive |
| c-KIT (d557-558) | KIT, exon 11 deletion | Standard transforming receptor | Constitutive |
| c-KIT (d557-558/V654A/A829P) | KIT, compound mutant | Resistance model | Constitutive |
| c-KIT (d557-558/V654A/D816A) | KIT, compound mutant | Resistance model | Constitutive |
| c-KIT (d557-558/V654A/D820A) | KIT, compound mutant | Resistance model | Constitutive |
| c-KIT (d557-558/V654A/D822K) | KIT, compound mutant | Resistance model | Constitutive |
| EpoR (murine and human) | Erythropoietin receptor | Activation-dependent | Ligand co-stimulation (EPO) |
| MPL | Thrombopoietin receptor | Activation-dependent | Ligand co-stimulation (TPO) |
| MPL+CALR (wild type) | MPL with wild-type calreticulin | Control Line | Requires IL-3 |
| MPL-CALR (L367fs*46) | MPL-CALR frameshift | Transformed, stimulus-independent | None required (IL-3 and TPO independent) |
* This is a focused, project-derived library. New oncogenic driver, fusion, and resistance-mutant lines are generated on request.
BaF3 Assay Mechanism
The overexpression of receptor tyrosine kinases enables the interleukin 3-dependent Ba/F3 cell line to grow without the supplement of interleukin 3. The inhibition of the activity of the transforming kinase leads to the loss of growth stimuli resulting in cell apoptosis.
Frequently asked questions
What is a BaF3 cell proliferation assay?
It is a functional, cell-based assay for kinase inhibitors. BaF3 cells engineered to depend on a transforming kinase are treated with a compound, and inhibition of that kinase removes the survival signal, so loss of proliferation reports on-target activity as an IC50.
Why are BaF3 cells used for kinase inhibitor screening?
BaF3 cells normally depend on interleukin-3, but expression of a constitutively active kinase makes them kinase-dependent instead. This provides a clean, single-driver background with no interference from other kinases, and rapid growth suitable for potency and resistance studies.
What does the assay measure?
Inhibitor potency as an IC50, derived from loss of cell proliferation. Proliferation is quantified by CellTiter-Glo luminescent ATP detection, with alternative readouts available.
How do you rule out non-specific cytotoxicity?
An optional, parallel arm supplemented with interleukin-3 restores IL-3-driven growth. If a compound still inhibits proliferation under IL-3 rescue, the effect is non-specific rather than on-target kinase inhibition.
What are activation-dependent models?
Some receptors, such as KIT wild type, EpoR, and MPL, do not transform BaF3 cells by overexpression alone and require concurrent ligand co-stimulation. These cytokine-receptor lines broaden the assay beyond standard transforming receptors.
Do you generate custom BaF3 lines?
Yes. New oncogenic driver, fusion, and resistance-mutant lines are built to order as a project deliverable. This bespoke, project-driven approach is the most common way programs engage the service.
Which readouts are available?
CellTiter-Glo luminescent ATP is standard. Alamar Blue, MTT, CyQuant, and IncuCyte real-time imaging are available as alternatives.
How long does the assay take?
Cells are dosed the day after seeding and incubated for 48 to 72 hours before the proliferation readout, with activation-dependent lines run under concurrent ligand stimulation.
